ArticleInternational ophthalmology2026
Relationship between albuminuria and primary open angle glaucoma in patients attending a Nigerian tertiary hospital.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrimary open-angle glaucoma (POAG) is a leading cause of irreversible blindness globally. Emerging evidence suggests glaucoma is a vasculopathy with associated systemic microvascular dysfunction. A known feature of endothelial dysfunction is transudation, typified by albuminuria. This aimed to determine the relationship between POAG and albuminuria in patients attending a Nigerian tertiary hospital with a view to enhancing the evaluation and management of POAG patients for blindness prevention, particularly in resource-limited settings.
methodsThis hospital-based, comparative cross-sectional study included 210 adults: 105 POAG patients and 105 age-and sex-matched non-glaucomatous participants. Data on demographics and medical history were collected using an interviewer-administered questionnaire. Blood samples were analyzed for fasting blood sugar, lipid profile, and estimated glomerular filtration rate (GFR). Spot urine samples were collected to determine albuminuria using the urinary albumin-to-creatinine ratio (UACR, mg/g), based on measurements of urinary albumin and creatinine.
resultsA total of 210 patients were enrolled. These included 45 males and 60 females in each study and control group (male-to-female ratio of 1:1.3). The mean age of POAG participants was 43.91 ± 14.8 years. Among POAG participants, 69 (65.7%) had mild, 26 (24.8%) had moderate, and 10 (9.5%) had severe POAG. A significantly higher proportion of albuminuria was observed in the POAG group (8 patients, 7.6%) compared to the non-glaucoma group (3 patients, 2.9%) (p = 0.049). The odds of albuminuria were nearly three times higher in participants with severe POAG compared to those with mild POAG (OR = 2.993; 95% CI, 1.003-7.574; p = 0.048), and participants with POAG were approximately 2.5 times more likely to have albuminuria compared to the non-glaucoma group (OR = 2.483; 95% CI, 1.071-4.552; p = 0.042). Median UACR was significantly higher in the POAG group (7.69 mg/g; interquartile range [6.2-10.3]) compared to the non-glaucoma group (3.83 mg/g; range [1.7-9.3]) (p < 0.001).
conclusionThis study demonstrated a significant association between POAG and albuminuria, with increasing severity of POAG correlating with higher odds of albuminuria. These findings suggest that albuminuria could serve as a systemic marker of disease severity in POAG. Early identification and monitoring of albuminuria in glaucoma patients may improve disease management and outcomes, potentially reducing the incidence of blindness.
Indexed as
Identifiers
42423790What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.